Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;54(12):2060-2071.
doi: 10.1038/s41409-019-0627-9. Epub 2019 Jul 30.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

Jan Styczynski  1 , Gloria Tridello  2 , Lidia Gil  3 , Per Ljungman  4   5 , Malgorzata Mikulska  6 , Katherine N Ward  7 , Catherine Cordonnier  8 , Rafael de la Camara  9 , Diana Averbuch  10 , Nina Knelange  11 , Gerard Socié  12 , Patrice Chevallier  13 , Didier Blaise  14 , Ibrahim Yakoub-Agha  15 , Edouard Forcade  16 , Jan Cornelissen  17 , Johan Maertens  18 , Eefke Petersen  19 , Stéphanie Nguyen-Quoc  20 , Hendrik Veelken  21 , Nicolaas Schaap  22 , Jakob Passweg  23 , Mauricette Michallet  24 , Nathalie Fegueux  25 , Eric Deconinck  26 , Nigel Russell  27 , Grzegorz Basak  28 , Peter Bader  29 , Silvia Montoto  30 , Nicolaus Kröger  31 , Simone Cesaro  2 ; Infectious Diseases Working Party EBMT
Affiliations

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

Jan Styczynski et al. Bone Marrow Transplant. 2019 Dec.

Abstract

The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.

PubMed Disclaimer

References

    1. Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, et al. Impact of donor epstein-barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2016;34:2212–20. - DOI
    1. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transpl. 2009;43:757–70. - DOI
    1. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059–67. - PubMed
    1. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16. - PubMed
    1. Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794–802. - DOI

MeSH terms

LinkOut - more resources